Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Why the study?
Does the CYP2C19*2 genotype affect the antiplatelet effect and clinical efficacy of clopidogrel therapy?
Population
Patients receiving clopidogrel therapy
Authors
Discussion
Loading...
Member takes
Implication
Warrants caution with clopidogrel in CYP2C19*2 carriers; leaves open whether genotype-guided therapy improves outcomes.
Structured PICO
Does the CYP2C19*2 genotype affect the antiplatelet effect and clinical efficacy of clopidogrel therapy?
P
Population
Patients receiving clopidogrel therapy
I
Intervention
CYP2C19*2 genotype
O
Outcome
Platelet response and cardiovascular outcomes
The CYP2C19*2 genotype is associated with reduced antiplatelet efficacy of clopidogrel and worse cardiovascular outcomes.
Cite This Study
Alan R. Shuldiner (2009) studied this question.